Medical Health & Life Science Research News

New report examines the non-alcoholic steatohepatitis pipeline market for therapeutics H2 2017

New report examines the non-alcoholic steatohepatitis pipeline market for therapeutics H2 2017

The Non-Alcoholic Steatohepatitis pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- Agency -.

Non-Alcoholic Steatohepatitis (NASH) Pipeline Review, H2 2017 report is complete research and development history and latest news and press releases.

Key players of H2 Non-Alcoholic Steatohepatitis Pipeline (NASH) are AdAlta Ltd, Albireo Pharma Inc, Allergan Plc, Alnylam Pharmaceuticals Inc, Amunix Operating Inc, Aquinox Pharmaceuticals Inc, Arcturus Therapeutics Inc, Ardelyx Inc, AstraZeneca Plc, Betagenon AB, BioLineRx Ltd, Bird Rock Bio Inc, BLR Bio LLC, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Can-Fite BioPharma Ltd, Cardax Inc, Carmot Therapeutics Inc, Catabasis Pharmaceuticals Inc, Cerenis Therapeutics Holding SA and more..

Get Non-Alcoholic Steatohepatitis (NASH) - Pipeline Review, H2 [email protected] www.reportsnreports.com/contacts/d…aspx?name=1125834 .

Non-alcoholic steatohepatitis (NASH) is liver inflammation caused by a buildup of fat in the liver.

- Agency -.

NASH can get worse and cause scarring of the liver, which leads to cirrhosis.

Symptoms of NASH include fatigue, weight loss for no clear reason, general weakness and an ache in the upper right part of belly. Risk factors include obesity, type 2 diabetes, high cholesterol and high triglycerides and metabolic syndrome.

Access Complete Report On Non-Alcoholic Steatohepatitis (NASH) - Pipeline Review, H2 2017: www.reportsnreports.com/purchase.aspx?name=1125834 .

Non-Alcoholic Steatohepatitis (NASH) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Non-Alcoholic Steatohepatitis (NASH) (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Non-Alcoholic Steatohepatitis (NASH) pipeline guide also reviews of key players involved in therapeutic development for Non-Alcoholic Steatohepatitis (NASH) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 3, 2, 2 and 1 respectively.

Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Scope

The report provides a snapshot of the global therapeutic landscape of Non-Alcoholic Steatohepatitis (NASH). The report reviews pipeline therapeutics for Non-Alcoholic Steatohepatitis (NASH) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages. The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.

The report reviews key players involved Non-Alcoholic Steatohepatitis (NASH) therapeutics and enlists all their major and minor projects. The report assesses Non-Alcoholic Steatohepatitis (NASH) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The report summarizes all the dormant and discontinued pipeline projects. The report reviews latest news related to pipeline therapeutics for Non-Alcoholic Steatohepatitis (NASH)

List of Figures
Number of Products under Development for Non-Alcoholic Steatohepatitis (NASH), H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017

News From

ReportsnReports - Industry Trends & ForecastsReportsnReports
Category: Market Research Publishers and RetailersCompany profile: ReportsnReports.com provides market research reports to industries, individuals and organizations with an objective of helping them in their decision-making process. Our library of 400,000+ industry & country research reports covers 5000+ micro markets.